ABSTRACT
The measurement of circulating tumour markers (TMs) for the diagnosis or monitoring of breast cancer has sometimes been considered of limited utility. In addition to the overinterpretation of irrelevant changes in marker levels, the characteristics of the patient, the disease or other pathologies that can modify them are often not considered in their evaluation. On the other hand, there are recent data on the relationship of TMs with molecular subtypes and on their prognostic value, the knowledge of which may improve their clinical utility. This consensus article arises from a collaboration between the Spanish Society of Laboratory Medicine (SEQCML) and the Spanish Society of Medical Oncology (SEOM). It aims to improve the use and interpretation of circulating TMs in breast cancer. The text summarizes the current knowledge and available evidence on the subject and proposes a series of recommendations mainly focussed on the indication, the frequency of testing and the factors that should be considered for correctly interpreting changes in the levels of TMs (AU)
Subject(s)
Humans , Biomarkers, Tumor/blood , Breast Neoplasms/blood , Breast Neoplasms/diagnosis , Societies, Medical , SpainABSTRACT
The measurement of circulating tumour markers (TMs) for the diagnosis or monitoring of breast cancer has sometimes been considered of limited utility. In addition to the overinterpretation of irrelevant changes in marker levels, the characteristics of the patient, the disease or other pathologies that can modify them are often not considered in their evaluation. On the other hand, there are recent data on the relationship of TMs with molecular subtypes and on their prognostic value, the knowledge of which may improve their clinical utility. This consensus article arises from a collaboration between the Spanish Society of Laboratory Medicine (SEQCML) and the Spanish Society of Medical Oncology (SEOM). It aims to improve the use and interpretation of circulating TMs in breast cancer. The text summarizes the current knowledge and available evidence on the subject and proposes a series of recommendations mainly focussed on the indication, the frequency of testing and the factors that should be considered for correctly interpreting changes in the levels of TMs.
Subject(s)
Biomarkers, Tumor/blood , Breast Neoplasms/blood , Breast Neoplasms/diagnosis , Breast Neoplasms/therapy , Female , Hematologic Tests/methods , Hematologic Tests/standards , HumansABSTRACT
In 2011, the Spanish Society of Medical Oncology (SEOM) first published a clinical guideline of venous thromboembolism (VTE) and cancer. This guideline was updated in 2014, and since then, multiple studies and clinical trials have changed the landscape of the treatment and prophylaxis of VTE in cancer patients. To incorporate the most recent evidence, including data from direct oral anticoagulants (DOACs) randomized clinical trials, SEOM presents a new update of the guideline.
Subject(s)
Clinical Trials as Topic/standards , Neoplasms/therapy , Practice Guidelines as Topic/standards , Venous Thromboembolism/therapy , Humans , Societies, MedicalABSTRACT
A 48-year-old woman with a diagnosis of breast carcinoma was treated with adjuvant chemotherapy through a central venous catheter with subcutaneous reservoir (Port-A-Cath). While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum. The patient recovered without sequelae with conservative therapy. Cytostatic extravasation via central catheter is an uncommon complication in clinical practice. In this paper we present the first doxorubicin extravasation through a central catheter in adults and review the only ten cases found in the literature (AU)
No disponible
Subject(s)
Humans , Female , Middle Aged , Extravasation of Diagnostic and Therapeutic Materials/complications , Breast Neoplasms/drug therapy , Vena Cava, Superior/injuries , Mediastinitis/etiology , Catheterization, Central Venous/adverse effects , Antineoplastic Agents/administration & dosage , Chest Pain/etiology , Respiratory Insufficiency/etiologyABSTRACT
Describimos un caso de ingesta accidental de arsenito sódico en un joven agricultor. Desarrolló como únicas manifestaciones un cuadro autolimitado de vómitos, dolor abdominal, cólico y alteraciones electrocardiográficas en la repolarización. Pudo darse el alta con recuperación completa. Se detectaron niveles tóxicos de arsénico en sangre y orina (AU)
We report a case of acute accidental sodium arsenite intake in a young farmer, with the only manifestations of a self-limited clinical picture of vomiting, colicky abdominal pain and electrocardiographic repolarisation disturbances. The patient was eventually discharged after complete recovery. Toxic arsenic levels were detected in plasma and urine (AU)
